2.87
-0.1(-3.37%)
Currency In USD
| Previous Close | 2.97 |
| Open | 2.97 |
| Day High | 3.02 |
| Day Low | 2.79 |
| 52-Week High | 4.08 |
| 52-Week Low | 1.15 |
| Volume | 984,823 |
| Average Volume | 967,580 |
| Market Cap | 396.87M |
| PE | -6.38 |
| EPS | -0.45 |
| Moving Average 50 Days | 2.79 |
| Moving Average 200 Days | 2.28 |
| Change | -0.1 |
If you invested $1000 in Compass Therapeutics, Inc. (CMPX) since IPO date, it would be worth $337.65 as of August 19, 2025 at a share price of $2.87. Whereas If you bought $1000 worth of Compass Therapeutics, Inc. (CMPX) shares 3 years ago, it would be worth $959.87 as of August 19, 2025 at a share price of $2.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
GlobeNewswire Inc.
Aug 13, 2025 2:28 AM GMT
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today
Compass Therapeutics Announces Proposed Public Offering
GlobeNewswire Inc.
Aug 12, 2025 8:01 PM GMT
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
GlobeNewswire Inc.
Aug 08, 2025 8:01 PM GMT
BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter